- Guillory, Xavier;
- Wolter, Madita;
- Leysen, Seppe;
- Neves, João Filipe;
- Kuusk, Ave;
- Genet, Sylvia;
- Somsen, Bente;
- Morrow, John Kenneth;
- Rivers, Emma;
- van Beek, Lotte;
- Patel, Joe;
- Goodnow, Robert;
- Schoenherr, Heike;
- Fuller, Nathan;
- Cao, Qing;
- Doveston, Richard G;
- Brunsveld, Luc;
- Arkin, Michelle R;
- Castaldi, Paola;
- Boyd, Helen;
- Landrieu, Isabelle;
- Chen, Hongming;
- Ottmann, Christian
Stabilization of protein-protein interactions (PPIs) holds great potential for therapeutic agents, as illustrated by the successful drugs rapamycin and lenalidomide. However, how such interface-binding molecules can be created in a rational, bottom-up manner is a largely unanswered question. We report here how a fragment-based approach can be used to identify chemical starting points for the development of small-molecule stabilizers that differentiate between two different PPI interfaces of the adapter protein 14-3-3. The fragments discriminately bind to the interface of 14-3-3 with the recognition motif of either the tumor suppressor protein p53 or the oncogenic transcription factor TAZ. This X-ray crystallography driven study shows that the rim of the interface of individual 14-3-3 complexes can be targeted in a differential manner with fragments that represent promising starting points for the development of specific 14-3-3 PPI stabilizers.